Stifel Initiates Coverage On Travere Therapeutics with Hold Rating, Announces Price Target of $22
Stifel analyst Alex Thompson initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Hold rating and announces Price Target of $22.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 160 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 184 companies set new 52-week lows.
Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know
Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Earnings Outlook For Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement.
Analysts estimate that Travere Therapeutics will report an earnings per share (EPS) of $-0.89.
SVB Leerink Maintains Outperform on Travere Therapeutics, Lowers Price Target to $38
SVB Leerink analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $45 to $38.
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA
Travere Therapeutics Inc (NASDAQ:TVTX) expects the November 17 PDUFA date for accelerated approval of lead drug sparsentan in IgA…
What 4 Analyst Ratings Have To Say About Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings within the last quarter:
FDA Requests For Additional Monitoring For Travere Therapeutics’ Sparsentan In Rare Kidney Disease
Following late-cycle review interactions with the FDA, Travere Therapeutics Inc (NASDAQ:TVTX) expects the previously assigned Prescription Drug User Fee Act…